The purpose of this retrospective observational study is to evaluate the characteristics of patients receiving Seroquel XR as treatment for their Major Depressive Disorder. The study will also investigate how the medication is used for these patients and if there are any differences in drug utilisation between the included countries. The study is observing patients initiating Seroquel XR during a 9 month period corresponding to 3 to 12 months following the launch of the product in each country for the MDD indication. A drug utilisation questionnaire will be used to collect study data from patients' medical records.
A Multinational, Multicenter, Retrospective, Observational Drug Utilisation Study of Seroquel Extended Release (XR) Prescribed by Psychiatrists as Treatment for Major Depressive Disorder (MDD) in Selected Countries in the European Union (EU)
Study Type
OBSERVATIONAL
Enrollment
814
Research Site
Dortmund, Germany
Patient age (mean and range)
Time frame: Baseline
Patient gender (%)
Time frame: Baseline
Diagnosis for which Seroquel XR was prescribed (% of Major Depressive Disorder- MDD)
Time frame: Baseline
Patients hospitalized for any psychiatric condition (n, %)
Time frame: follow-up up to nine months
Daily dose of Seroquel XR (mode and range)
Time frame: follow-up up to nine months
Patient referral pathway (%)
Time frame: Baseline
Participating psychiatrist practice setting (%)
Time frame: Baseline
Percent of patients experiencing psychotic symptoms at initiation of Seroquel XR (n, %)
Time frame: Baseline
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.